Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

Depo-Medrone is indicated for the symptomatic treatment of; rheumatic disorders, collagen diseases, dermatological diseases, allergic states, gastrointestinal disease, respiratory disease. Depo-Medrone may be used by any of the following routes; intramuscular, intra-articular, periarticular, intrabursal, intralesional or into the tendon sheath.

Arthritis presents a spectrum of treatment and lifestyle challenges

Rheumatoid arthritis (RA) is associated with reduced mobility, loss of time at work, and diminished quality of life (QoL)

  • Patients with RA experience restricted mobility and concomitant pain as a result of irreversible joint damage1
  • Almost 30% of patients with RA stop working within one year of diagnosis2
  • RA is associated with poorer psychosocial well-being, decreased life satisfaction and emotional distress3

Osteoarthritis (OA) has an adverse impact on patients’ physical and psychological health

  • 71% of people with OA are in constant joint pain, which equates to 6 million people in the UK
  • Joint pain and reduced function affect an individual’s social life and limit their independence
  • Joint pain comorbidity (JPC) is common in patients with knee OA and is negatively associated with health-related QoL5

Steroid injections, like Depo-Medrone6, are widely used o treat musculoskeletal problems like osteoarthritis (OA)7

Watch 3 short videos showing how to inject into the knee, shoulder 
or elbow.

Watch injection techniques

Resources & Training

Find related information and test your knowledge with bespoke training modules

Find out more

Stock Hub

Register here to receive real time stock information and email alerts 

Access the Stock Hub

References

  1. Breaking down barriers: Rheumatoid arthritis and public awareness. NRAS. 2013. Available at: https://www.nras.org.uk/publications/breaking-down-barriers-public-awareness-of-rheumatoid-arthritis-report. Accessed November 2019.
  2. I want to work survey. NRAS. 2007. Available at: https://www.nras.org.uk/publications/i-want-to-work-survey. Accessed November 2019.
  3. Emotional health & well-being matters. NRAS. 2018. Available at: https://www.nras.org.uk/publications/emotional-health-well-being-matters. Accessed October 2019.
  4. Arthritis Care; OA Nation Report 2012. Available at: https://issuu.com/arthritiscare/docs/oa_nation_2012_report. Accessed November 2019.
  5. Hoogeboom TJ et al. Rheumatology. 2013;52:543–46.
  6. Depo Medrone Summary of Product Characteristics 
  7. Housman L, Arden N et al. Intra-articualr hylastan versus steroid for knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc 2014; 22(7): 1684-1692